Breakthrough! Sinopharm's first export to Macau - quadrivalent influenza subunit vaccine supports health protection in Macau region.

Key Step Taken in Internationalization Strategy Recently, AB&B BIO-TECH-B (02627) independently developed a quadrivalent influenza virus subunit vaccine - Huierkangxin successfully arrived in the Macao Special Administrative Region and completed customs clearance, achieving its first export and officially entering the Macao market. This is not only an important symbol of the company's scientific research strength and production quality receiving international recognition, but also a key milestone in the company's advancement of global layout. The quadrivalent influenza virus subunit vaccine (Huierkangxin) supplied to Macao this time adopts advanced third-generation influenza vaccine technology, containing the main surface antigens of two types of influenza A and two types of influenza B virus, with high purity, good safety, strong immunogenicity, and other characteristics. Compared to traditional vaccines, this product further optimizes the process, significantly improves vaccination safety and protection effects, and is suitable for various groups, including high-risk populations. Currently in the flu season, the Macao Special Administrative Region continues to strengthen the prevention and control of respiratory infectious diseases. The timely introduction of this vaccine will provide high-quality and reliable immunization options for Macao residents, helping to strengthen the local public health defense line. Successful Launch Ceremony, Working Together to Build a Healthy Macao On December 4th, the vaccine successfully held its first vaccination ceremony at the Kiang Wu Hospital in Macao. The event conveyed the concept of "actively being healthy and preventing actively" to all walks of life in Macao, vividly interpreting our company's corporate vision of "bringing global innovative vaccines to China, and bringing China's high-quality vaccines to the world". The company's head of overseas business expressed in his speech: "We are honored to bring this advanced subunit influenza vaccine to our compatriots in Macao. This cooperation is not only a breakthrough in market expansion, but also an important step towards realizing our vision of bringing China's high-quality vaccines to the world. We will continue to support Macao's public health and jointly protect the health of Macao residents." Continuously innovating, moving towards a broader international stage The successful delivery and use of the vaccine in Macao this time is a vivid demonstration of the company's solid promotion of its internationalization strategy. So far, the company has established cooperative relationships with multiple countries and regions. In the future, the company will continue to adhere to innovation-driven, continuously improve the vaccine product pipeline, promote more high-quality products to serve the global market, and contribute China's strength to building a global community of health. This cooperation has accumulated valuable experience for the company to deepen its market layout in the Greater Bay Area of Guangdong, Hong Kong, and Macao, expand international channels, and provide a reliable Chinese solution for global influenza prevention and control.